British Patient Capital approves $35m commitment

The UK government-backed investor has backed a cybersecurity-focused venture capital fund.

Institution: British Patient Capital
Headquarters: Sheffield, United Kingdom
AUM: £2.5 billion

British Patient Capital, a subsidiary of British Business Bank, has committed $35 million to The Evolution Technology Fund II, according to a recent press release.

The Evolution Technology Fund II is targeting $250 million in equity capital, with investments focused on software and cybersecurity companies globally. The fund’s portfolio companies include the likes of CounterCraft, a UK based cybersecurity firm.

British Patient Capital tends to focus its private equity fund commitments on venture capital and growth equity vehicles.

Platinum subscribers may click here for the investor’s full profile, including key contacts, allocation strategy and fund investments.